Brain Diseases
Phase II: Autologous BM-MSC combining Rehabilitation for children with cerebral palsy
Prof Nguyen Thanh Liem
A randomized clinical trial in 58 patients comparing intrathecal autologous bone marrow mononuclear cell infusion combined with rehabilitation with a control group. Group A receives infusions at baseline and after 6 months, while Group B serves as the control for 9 months and then receives infusions at months 9 and 15, with follow up until 18 months.
Controlled clinical: UC-MSC treating ischemic stroke
Prof. Nguyen Thanh Liem & Dr. Phung Nam Lam
Outcomes of umbilical cord blood-derived mesenchymal stem cell infusion in the treatment of neurological sequelae after ischemic stroke: A controlled clinical trial
Matched case-control: Autologous BM-MSC treating neurological sequelae post TBI
Prof. Nguyen Thanh Liem
Outcomes of safety and efficacy of autologous bone marrow mononuclear cell infusion in the treatment of neurological sequelae after traumatic brain injury: matched case-control clinical trial
To evaluate the safety and efficacy of autologous bone marrow mononuclear cell administration in treating neurological sequelae after traumatic brain injury
Autologous BM-MSC therapy combining Psychological education treating Autism
Prof. Nguyen Thanh Liem
A randomized clinical trial in 54 children with autism spectrum disorder aged 3 to 7 years compared two intrathecal infusions of autologous bone marrow mononuclear cells given six months apart plus educational intervention with education alone. Over 12 months of follow up, the treatment was safe and resulted in reduced DSM 5 and CARS severity scores and improved CGI and VABS II outcomes.